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Heterogeneity and Phenotypic Plasticity of
Glial Cells in the Mammalian Enteric
Nervous System
Werend Boesmans,1 Reena Lasrado,2 Pieter Vanden Berghe,1 and Vassilis Pachnis2
Enteric glial cells are vital for the autonomic control of gastrointestinal homeostasis by the enteric nervous system. Several dif-
ferent functions have been assigned to enteric glial cells but whether these are performed by specialized subtypes with a dis-
tinctive phenotype and function remains elusive. We used Mosaic Analysis with Double Markers and inducible lineage tracing
to characterize the morphology and dynamic molecular marker expression of enteric GLIA in the myenteric plexus. Functional
analysis in individually identified enteric glia was performed by Ca21 imaging. Our experiments have identified four morpho-
logically distinct subpopulations of enteric glia in the gastrointestinal tract of adult mice. Marker expression analysis showed
that the majority of glia in the myenteric plexus co-express glial fibrillary acidic protein (GFAP), S100b, and Sox10. However,
a considerable fraction (up to 80%) of glia outside the myenteric ganglia, did not label for these markers. Lineage tracing
experiments suggest that these alternative combinations of markers reflect dynamic gene regulation rather than lineage
restrictions. At the functional level, the three myenteric glia subtypes can be distinguished by their differential response to
adenosine triphosphate. Together, our studies reveal extensive heterogeneity and phenotypic plasticity of enteric glial cells
and set a framework for further investigations aimed at deciphering their role in digestive function and disease.
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Introduction
Glial cells are essential for the organization and functionof the nervous system (Jessen, 2004). In addition to
their “traditional” roles in providing nourishment and sup-
port for neurons, glial cells regulate synaptic transmission,
maintain the blood-brain barrier, mediate communication
between the nervous and immune systems and monitor the
nutritional state of organisms (Allaman et al., 2011; Giaume
et al., 2010; Perea et al., 2009). Highlighting their critical
role during embryogenesis and in postnatal life, several
developmental, degenerative, and inflammatory disorders of
the nervous system have been associated with deficits in glial
cell function (Barres, 2008; Lee et al., 2000; Lemke, 2001).
Enteric glial cells (EGCs) constitute a major population of
peripheral glia that is located within the ganglia of the myen-
teric and submucosal plexus of the enteric nervous system
(ENS) and in extraganglionic sites, such as the smooth muscle
layers and the mucosa (Gershon and Rothman, 1991;
Gulbransen and Sharkey, 2012; Ruhl et al., 2004). A series of
studies has demonstrated that EGCs are critical for the regula-
tion of gut motility, the secretory and absorptive functions of
the intestinal epithelium and the host’s defense against patho-
gens (De Giorgio et al., 2012; Gulbransen and Sharkey, 2012;
Neunlist et al., 2013). Enteric neurons and EGCs are derived
from neural crest cells which emerge during embryogenesis
from the vagal and sacral level of the neural tube and colonize
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uniformly the entire length of the gastrointestinal tract (Heanue
and Pachnis, 2007; Sasselli et al., 2012). Although diversity of
enteric neuron subtypes has been studied intensively in mam-
mals (Furness, 2000), our understanding of the extent, the ori-
gin and physiological significance of EGC diversification
remains unclear. Pioneering work from Hanani and Reichen-
bach (1994) proposed a classification scheme for EGCs that was
based on cell morphology and location within the plexus. How-
ever, the recognition that essential subsets of EGCs are located
outside the ENS plexus, the advent of genetic tools that allow
detailed characterization of EGCs and recent progress in under-
standing their physiological properties, warrant a reexamination
of EGC subtype classification in a manner that takes into con-
sideration morphological features, distribution within the gut
wall as well as molecular and physiological attributes. Moreover,
given that the gut constitutes one of the most dynamic organs
of the body which adjusts constantly to the volatile microenvir-
onment of the lumen (unpredictable availability of nutrients,
changing populations of commensal bacteria, and exposure to
pathogenic microorganisms), any classification scheme for
EGCs must also consider the potential plasticity of subtypes
identified at any given moment.
In the present study, we have carried out high resolution
morphological characterization of EGC subtypes by combining
Mosaic Analysis with Double Markers (MADM) with immu-
nostainings for glial markers. In addition, we have examined
the physiological properties of different subtypes of myenteric
glia using Ca21 imaging on live tissue. Furthermore, using
Cre/LoxP technology we have carried out in vivo fate mapping
and inducible lineage tracing of defined subsets of EGCs with
the aim of exploring their plasticity in the myenteric ganglia.
Our experiments extend previous studies on the morphological
and physiological characterization of EGCs and highlight a
novel subtype of extraganglionic glia which is located within
the plexus. Moreover, our experiments have revealed previously
unrecognized plasticity in the molecular phenotype of defined
glial subpopulations of the mammalian ENS.
Materials and Methods
Animals
All experimental procedures were carried under a UK Home Office
Project license and approved by the local Animal Ethics Committees
of the National Institute of Medical Research and the University of
Leuven. Animals were housed at an ambient temperature of 22C–
24C on a 12:12 hr light/dark cycle. Drinking water and laboratory
chow were provided ad libitum. The Sox10::Cre (Matsuoka et al.,
2005), MADM-6GR and MADM-6RG (Zong et al., 2005), hGFAP::-
CreERT2 (Ganat et al., 2006), and the Rosa26R-YFP (Srinivas et al.,
2001) transgenic mice have been described previously. In vivo label-
ing of EGCs in hGFAP::CreERT2; Rosa26R-YFP adult animals was
achieved by intraperitoneal injections of 0.1–0.2 mg/g of 4-hydroxy
tamoxifen (4-OHT; Sigma), which was dissolved in an ethanol/
sunflower oil (1:9) mixture at 10 mg/mL (Laranjeira et al., 2011).
Control mice were not injected or injected with an ethanol/
sunflower oil (1:9) mixture.
Immunofluorescence of Adult Myenteric Plexus
Preparations, Confocal Image Acquisition and
Processing
Gut tissue was cut into 2 cm long pieces and mounted over a 1 mL
pipette. An incision was made along the mesenteric border and a
cotton swab soaked in PBS was used to roll out the longitudinal
muscle with adherent myenteric plexus from the underlying tissue.
Isolated adult myenteric plexus preparations were stretched and
pinned onto Sylgard dishes (Sylgard 184 Elastomer, Dow Corning)
using insect pins (0.2 mm, Agar Scientific) and fixed in ice-cold
paraformaldehyde (4% in PBS) for 2 hr at 4C. Fixed tissue samples
were permeabilized in 0.3% TritonX-100 (Sigma) in PBS (PBT) and
incubated in blocking solution (5% Normal Donkey Serum in PBT,
Jacksons ImmunoResearch Laboratories). Primary antibodies
(Table 1) were diluted in blocking solution and applied overnight at
4C. Samples were washed in PBT and appropriate secondary
antibodies were applied. The GFP antibodies were used to detect
expression of the YFP reporter, and the two terms are used inter-
changeably. Secondary antibodies were goat or donkey hosted Alexa-
Fluor 488, Alexa Fluor 568, Alexa Fluor 594, and Cy5 (all 1:500;
Invitrogen and Jackson ImmunoResearch). Samples were mounted
with VectashieldTM mounting medium (Vector Labs).
Confocal and 3-D Images were acquired with Leica TCS SP5
(CIAL facility, NIMR, UK) and Zeiss LSM780 2-photon (Cell
Imaging Core, KU Leuven) confocal microscopes using standard
excitation and emission filters, assisted with Leica Application Suite
Advanced Fluorescence (LAS AF) and Zeiss ZEN software, respec-
tively. All images were processed with either Adobe Photoshop CS4
(Adobe Systems) or ImageJ (Wayne Rasband, NIH). 3-D reconstruc-
tions and morphological quantifications were obtained with Imaris
7.7 (Bitplane AG) after deconvolution using Huygens Professional
(Scientific Volume Imaging).
Enteric Glial Cell Cultures
Primary cultures containing both enteric neurons and EGCs were pre-
pared as described previously (Boesmans et al., 2013b). Briefly, tissue
preparations of longitudinal muscle with adherent myenteric plexus
were isolated from the ileum and collected in previously oxygenated
Krebs solution (95% O2 to 5% CO2, 4
C). After washing, tissue prep-
arations were digested in a collagenase (14.67 mg/mL)/protease (10
mg/mL)/albumin (5% in PBS) (Invitrogen) mixture for 8 min at
37C. After stopping the enzymatic digestion by adding a Krebs solu-
tion with 10% foetal bovine serum (FBS) and washing by centrifuga-
tion the pellet was resuspended in medium (DMEM F-12) enriched
with 10% FBS, 1% glutamine and 0.5% pen/strep (Lonza Group
Ltd). The cells were plated on glass coverslips coated with poly-D-
lysine hydro bromide (0.5 mg/ml in borate buffer) and laminin (20
mg/ml in PBS) (Sigma) and cultured at 37C (95% O2 to 5% CO2).
After 24 hr, the medium was replaced by a serum-free medium supple-
mented with nerve growth factor (0.05%, Alomone Laboratories), N2
(0.2%), and G5 (0.2%) (Invitrogen).
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Live Calcium Imaging
Ca21 imaging of EGCs and subsequent analysis was performed as
previously described (Boesmans et al., 2013b; Vanden Berghe et al.,
2008). The proximal colon of MADM-6GR/RG; Sox10-Cre mice was
pinned flat in a Sylgard-lined dish filled with Krebs solution
(bubbled with 95% O2 to 5% CO2) and the mucosa and longitudi-
nal muscle layer were carefully removed. Myenteric plexus prepara-
tions were loaded with 1 lM Rhodamine 2 (Rhod2, RT, 20 min,
TEFLabs) in Krebs with cremophor EL (0.01%, Fluka). During
recordings, a constant flow (1 mL/min) of Krebs (with or without
10 lM ATP, Sigma) solution was maintained via a gravity-fed elec-
tronic valve system. 1 lM nifedipine (Sigma) was added to the
Krebs solution to inhibit smooth muscle contractions. Images were
recorded on an upright Axiovert 200M microscope (Zeiss) with a
Poly V xenon monochromator (TILL Photonics) and water dipping
lens (20X, 1.0 NA, Zeiss). MADM-induced GFP and Rhod2 were
excited at 475 nm and 580 nm and captured at 525/50 nm (still)
and 645/75 (at 2 Hz), respectively, on a Sensicam-QE CCD camera
(PCO) using TillVisION (TILL Photonics). Calcium imaging analy-
ses were performed with custom-written routines in Igor Pro (Wave-
matrics). Regions of interest were drawn, after which average Ca21
signal intensity was calculated, normalized to the initial Rhod2 val-
ues and reported as DF/F0. Cells were considered as responders
when the Rhod2 signal rose above baseline plus 3 times the intrinsic
noise (standard deviation) during the recording.
Statistical Analysis
Analysis was performed on a total sample of cells (as reported) that
were obtained from at least three animals per genotype or experi-
mental condition. Differences between data sets were determined by
ANOVA followed by Bonferroni post-hoc test (for multiple compari-
son tests). Chi-square or Fisher’s exact tests were performed to
compare proportions. A P value <0.05 was considered to be signifi-
cant. Significant differences with P < 0.05, 0.01, and 0.001 were
indicated with *, **, and ***, respectively. Statistical analysis was per-
formed with Microsoft Excel (Microsoft) and GraphPad Prism
(GraphPad Softwares). Error bars represent the standard error of the
mean (SEM).
Results
High Resolution Labeling of EGCs Using Mosaic
Analysis With Double Markers (MADM)
Glia-specific molecular markers that are expressed widely in
the central and peripheral nervous system have been used
extensively for the identification and characterization of
EGCs in mouse embryos and adult animals. Among such
markers are the intermediate filament glial fibrillary acidic
protein (GFAP) and the Ca21-binding protein S100b, which
are expressed by committed EGC progenitors and differenti-
ated EGCs (Ferri et al., 1982; Jessen and Mirsky, 1980;
Young et al., 2003). In addition to these cytoplasmic proteins,
the nuclear localized transcription factor Sox10 is expressed
by multipotential ENS progenitors (Bondurand et al., 2003;
Paratore et al., 2002) and is maintained in immature and
mature EGCs (Hoff et al., 2008; Laranjeira et al., 2011;
Young et al., 2003). These markers, which are usually identi-
fied by immunostaining on fixed gut preparations, are either
unsuitable for morphological characterization of EGCs
(Sox10) or are expressed by contiguous glial cells thus pre-
cluding studies that require single cell resolution. We rea-
soned therefore that sparse labeling of EGCs with genetically
encoded fluorescent reporters would facilitate high resolution
TABLE 1: Primary Antibodies Used for Immunofluorescence Labeling
Antigen Host Dilution Source
S100b Rabbit 1:500 DAKO
GFAP Rabbit 1:500 DAKO
GFAP Chicken 1:300 Abcam
Sox10 Goat 1:200 Santa Cruz Biotechnologies
GFP Rabbit 1:1000 Invitrogen
GFP Rat 1:1000 Nacalai Tesque
TuJ1 Mouse 1:1000 Covance
peripherin Goat 1:500 Santa Cruz Biotechnologies
nNOS Rabbit 1:400 Santa Cruz Biotechnologies
neurofilament-200 Chicken 1:500 Abcam
CD31 Rabbit 1:500 Abcam
myc Goat 1:500 Novus Biologicals
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morphological and physiological studies on both fixed and
live tissue. To achieve this, we employed MADM, a sparsely
labeling genetic system in which Cre-dependent interchromo-
somal recombination restores expression of fluorescent lineage
tracers encoded by reciprocally chimaeric nonfunctional cas-
settes targeted to the same locus on homologous chromo-
somes (Zong et al., 2005). For our current studies we used
the original MADM alleles (MADM-6GR and MADM-6RG)
in which chimaeric GFP/RFP-Myc vectors have been inserted
into the ubiquitously expressed Rosa26 locus on mouse chro-
mosome 6 (Zong et al., 2005). Introduction of the Sox10::Cre
transgene, which drives expression of Cre recombinase in all
neural crest cell lineages and peripheral glial cells (Laranjeira
et al., 2011; Matsuoka et al., 2005), into MADM-6GR/RG
compound heterozygous mice (designated hereafter Sox10-
CrejMADM), allowed us to mark with GFP or RFP-myc or
both, isolated EGCs (Fig. 1a) and enteric neurons (which
originate from marked Sox101 progenitors, Supp. Info.
Fig. 1a). Since detection of RFP in Sox10CrejMADM mice
depends on immunostaining with anti-myc antibodies (Supp.
Info. Fig. 1b), all studies reported here are based on the
identification of GFP on fixed or live gut tissue preparations.
The glial identity of all GFP1 cells analyzed from
Sox10CrejMADM mice has been confirmed by double
immunostaining with S100b-specific antibodies (Fig. 1b–e).
Characterization of GFP-expressing cells in whole-
mount preparations of the different layers of the gut wall
from Sox10CrejMADM mice, allowed us to identify four
EGC subtypes on the basis of morphology and location.
Restricted within the ganglia of the myenteric and submuco-
sal plexus were numerous GFP1 cells bearing multiple irregu-
lar and highly branched processes which extended in all
directions up to 42.5 6 2.5 lm away from the cell body
(Fig. 1b,f; Table 2; Supp. Info. Movie 1). The processes of
FIGURE 1: Single-cell labeling of enteric glia in Sox10CrejMADM mice. (a) Individual EGCs expressing GFP (green) can be identified
within and outside the ganglia and interconnectives of the myenteric plexus (Tuj1, red). (b–e) Double labeling of the different morpho-
logical subtypes of EGCs (type I–IV) expressing MADM-induced GFP (green) with the glial marker S100b (gray). (f–i) Deconvolved maxi-
mum projections (top) and 3-D reconstructions (bottom) of type I (f), II (g), III (h), and IV (i) EGCs identified in the ENS of
Sox10CrejMADM mice. See also Supp. Info. Movies 1–4. Scale bars: 50 lm (a), 20 lm (b–i). [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
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these intraganglionic glial cells often terminate with “end-
feet” like structures and were intermingled with processes
from other neighboring EGCs and were contacting multiple
neurons within the same ganglion (Fig. 2a; Supp. Info.
Movie 2). These astrocyte-like glial cells correspond to the
“protoplasmic” or type-I EGCs described previously by
Hanani and Reichenbach (1994). These authors provided also
the first description of the “fibrous” or type-II EGC found
within or at the edges of the interganglionic connectives.
Using GFP expression as marker, we have confirmed that this
EGC subtype has lanky processes that emerge mostly from
one side of the cell and run for 53.9 6 6.1 lm in parallel to
each other and to the neuronal fibers of the interganglionic
strands (Fig. 1c,g; Table 2; Supp. Info. Movie 3). These glial
cell processes contact most neural fibers but they do not wrap
around them in a manner analogous to the ensheathing of
peripheral nerve fibers by Schwann cells (Fig. 2b; Supp. Info.
Movie 4). In addition to the type-I and type-II EGCs we
have uncovered a morphologically distinct glial subtype which
is at the level of the myenteric and submucosal plexus but lies
outside the ganglia and the interganglionic connectives
(Fig. 1a). This subtype, designated hereafter as type-III,
exhibits mainly four major processes (87.6 6 5.3 lm) with
secondary branching (Fig. 1d,h; Table 2; Supp. Info.
Movie 5). Type-III EGCs appear to form a matrix in the
extraganglionic region, and remain in close association with
neuronal fibers running along their processes (Fig. 2c). In
addition, the processes of type-III EGCs are often seen wrap-
ping around small blood vessels (Fig. 2d). EGCs with a simi-
lar morphology have been described previously as a distinct
subtype within the lamina propria of the mucosa and have been
termed “mucosal” or type-III EGCs (Gulbransen and Sharkey,
2012; Savidge et al., 2007). Given their morphological similar-
ities but distinct location, we propose to discriminate between
the mucosal and plexus positioned type-III EGCs by referring
to them as type-IIIMucosa and type-IIIMP/SMP, respectively.
Finally, our MADM labeling system also revealed EGCs with a
characteristic bipolar morphology which were located within the
circular and longitudinal smooth muscle layers along nerve
fibers (Fig. 1e,i; Table 2; Supp. Info. Movie 6). These cells
correspond to the type-IV EGCs described previously (Gulbran-
sen and Sharkey, 2012; Vanderwinden et al., 2003). Taken
together, our experiments extend previous studies on the classifi-
cation of EGCs and demonstrate that MADM-mediated fluo-
rescent labeling can be used effectively for high resolution
morphological analysis of individual glial cells throughout the
mammalian ENS. All our subsequent studies were carried out
on glial cells (types I–III) of the myenteric plexus.
Differential Expression of Glial Markers in Subtype
Populations of Myenteric Glia
So far, the markers GFAP, S100b, and Sox10 have been used
interchangeably for the identification of EGCs. To determine
whether the EGC subtypes within the myenteric plexus can be
distinguished by the differential expression of these commonly
used glial markers, we performed double immunostaining of
myenteric plexus preparations isolated from the intestine of
P90 mice using combinations of marker-specific antibodies.
First, we quantified the expression of GFAP and S100b.
Whereas, the majority of type-I EGCs residing in the myen-
teric ganglia co-expressed GFAP and S100 (GFAP1/S100b1;
55.8 6 5.2%), the remainder cells of this subtype population
expressed either S100b (GFAP2/S100b1; 29.9 6 4.4%) or
GFAP (GFAP1/S100b2; 14.3 6 3.9%) only (Fig. 3a,b).
Interestingly, the percentage of GFAP2/S100b1 cells among
the type-II and type-IIIMP EGCs was significantly higher (59.6
6 1.6% and 78.9 6 0.7%, respectively) relative to that in
type-I glia. Notably, a relatively high percentage of GFAP1/
S100b2 cells (50%) displayed remarkably high immunoreac-
tivity for GFAP (Fig. 3a, arrow). Next, we compared the
expression of GFAP and Sox10. Similar to our findings with
the GFAP/S100b combination, in all three EGC subtypes we
identified cells that expressed either one or both of these
markers. Thus, 74.4 6 2.4% of the type-I glia were GFAP1/
Sox101 but only 19.3 6 1.5% were GFAP2/Sox101 and 6.2
6 0.9% expressed only GFAP (Fig. 3c,d). In type-II EGCs
TABLE 2: Morphometric Analysis of Enteric Glia Subtypesa
Type-I Type-II Type-III Type-IV One-way ANOVA
Cell body volume (lm3) 335.4 6 36.0 241.9 6 15.4 275.7 6 18.8 277.6 6 44.5 P 5 0.0869
Total cell volume (lm3) 677.0 6 97.2 699.5 6 144.4 791.7 6 60.4 490.0 6 33.0 P 5 0.5547
Average process length (lm) 30.9 6 1.4 53.9 6 6.1 87.6 6 5.3 124.0 6 11.4 P < 0.0001
Maximal process length (lm) 42.5 6 2.5 77.6 6 9.7 118.1 6 8.2 138.1 6 15.5 P < 0.0001
Largest cell axis (lm) 52.9 6 4.2 88.0 6 11.7 144.7 6 10.8 229.0 6 24.4 P < 0.0001
aData are represented as average 6 SEM.
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the percentage of GFAP2/Sox101 cells increased to 46.4 6
3.7% at the expense mostly of the double positive population,
whereas in type-IIIMP glia it increased further to 67.6 6 5.1%
at the expense of both the double positive and the GFAP-only
population (Fig. 3d). The relative percentage of GFAP2/
Sox101 cells observed in the three types of glial cells mirrors
the relative percentage of GFAP2/S100b1 glia (Fig. 3b) sug-
gesting that the majority of S100b1 glial cells co-express
Sox10. This was confirmed by double immunostaining with a
combination of S100b and Sox10 antibodies which demon-
strated that virtually all S100b1 cells co-expressed Sox10 (Fig.
3e,f). Nevertheless, a small population of type-I (5.5 6 1.5%)
and type-II (7.4 6 1.4%) glia expressed only Sox10 (S100b2/
Sox101) and this fraction increased slightly in type-IIIMP
EGCs (10.7 6 1.9%, Fig. 3f). Taken together, these data indi-
cate that none of the markers examined here (and commonly
used for the identification of EGCs) can uniquely identify any
of the morphologically distinct glial subtypes within the
myenteric plexus. Nevertheless, the differential abundance of
cells expressing combinations of GFAP, S100b, and Sox10
within the glial subtypes I–III of the myenteric plexus suggests
that glia-specific gene expression in the mammalian gut is
highly dynamic and is influenced at the population level by
spatially and temporally controlled factors.
Differential Response of EGC Subtypes to
Purinergic Activation
To investigate whether, in addition to the differential marker
expression, EGC subtypes are also characterized by distinct
physiological properties, we performed Ca21 imaging
FIGURE 2: Interaction between enteric neurons and glia in the myenteric plexus of Sox10CrejMADM mice. (a) Type-I EGC (green) in
close apposition with enteric neurons labeled for the pan-neuronal marker peripherin (red) within a myenteric ganglion. (b) Type-II EGC
(green) located in an interganglionic connective positive for neurofilament-200 (red). (c) Type-III EGC (green) positioned at the level of
the myenteric plexus with several of its processes contacting nitrergic (nNOS, red) nerve fibers and varicosities (arrows). (d) Type-III EGC
(green) wrapping around a blood vessel (CD31, red). See also Supp. Info. Movies 5 and 6. Scale bars: 20 lm. [Color figure can be viewed
in the online issue, which is available at wileyonlinelibrary.com.]
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experiments on fresh preparations of myenteric plexus. Given
the established paradigm of purinergic neuron-to-glia commu-
nication in the ENS (Boesmans et al., 2013b; Gomes et al.,
2009; Gulbransen and Sharkey, 2009), we decided to test
whether the three myenteric glia subtypes respond differently
to purinergic receptor stimulation. For this, we loaded myen-
teric plexus preparations dissected from Sox10CrejMADM
mouse colon with the red Ca21 indicator Rhodamine-2.
This enabled us to unambiguously measure the changes in
intracellular Ca21 concentration upon ATP (10 lM, 20 s)
stimulation in individual cells that belong to the three EGC
subtypes of the myenteric plexus (Fig. 4). We found that the
majority (86.8%) of intraganglionic type-I EGCs respond with
a Ca21 transient (DF/F0: 7.0 6 0.9%) when challenged with
FIGURE 3: Differential expression of GFAP, S100b, and Sox10 in enteric glia of the myenteric plexus of the ileum. (a) Double immunostain-
ing for GFAP (green) and S100b (gray). Although most EGCs express both markers, EGCs only positive for GFAP (arrow) or S100b (arrow-
heads) can be observed. (c) Double immunostaining for GFAP (green) and Sox10 (red). Note the presence of EGCs expressing only GFAP
(arrows) or Sox10 (arrowhead). (e) Double immunostaining for S100b (gray) and Sox10 (red). The majority of cells were found positive for
both S100b and Sox10. A small proportion of cells positive for Sox10 did not express S100b (arrows). EGCs positive for S100b but not for
Sox10 were not observed. (b, d, f) Quantification of single and double positive cells in the different subtype populations of EGCs in the
myenteric plexus (Chi-square: b: P < 0.0001, d: P < 0.0001, f: P 5 0.0388). A total of 1,851 (b), 2,420 (d), and 1,792 (f) cells were counted
per co-staining. Scale bars: 50 lm. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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ATP (Fig. 4d–g). Although purinergic receptor stimulation
induced Ca21 rises in a similar proportion (73.9%) of type-II
EGCs in the interconnectives fiber tracts, Ca21 transient
amplitudes were significantly lower (DF/F0: 3.1 6 0.6%)
(Fig. 4f,g). Among type-IIIMP EGCs located in the intergan-
glionic space, only 34.6% displayed Ca21 rises
(DF/F0: 1.9 6 0.3%) upon ATP stimulation (Fig. 4f,g). Thus,
compared to type-I and type-II EGCs, extraganglionic type-
IIIMP cells display a decreased responsiveness to purinergic
receptor stimulation. These data are consistent with our
FIGURE 4: Intracellular Ca21 imaging in individually identified enteric glia. (a–d) Representative images of a myenteric plexus preparation
isolated from a Sox10CrejMADM mouse and loaded with the fluorescent Ca21 indicator Rhodamine-2 (Rhod2, a) that illustrate the three
subtypes of EGCs in the myenteric plexus (arrowheads) expressing GFP (b, c). Cells responding to ATP stimulation (10 lM, 20 s, d) were
falsely colored in red by an activity-over-time operation. (e) ATP-evoked [Ca21]i response of GFP-expressing cells depicted in (a–d,
arrowheads, color-coded Rhod2 traces match the three subtypes depicted in (b). (f) Maximal amplitude of the ATP-induced Ca21 tran-
sient in the three morphologically different subtypes (ANOVA: P 5 0.0004, **Bonferonni post-hoc). (g) Proportion of cells that displayed
(or not) a Ca21 transient upon ATP stimulation (**Fisher’s exact). The total number of cells responding and nonresponding to ATP is
shown. Scale bar: 20 lm. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
8 Volume 00, No. 00
morphological analysis and argue that the constituent popula-
tions of EGCs in the myenteric plexus can be distinguished on
the basis of neurotransmitter responses.
Sox10 Negative EGCs are Derived From
Sox10-Expressing Progenitors
Since Sox10 is known to mark all glia of the peripheral nerv-
ous system (Herbarth et al., 1998; Pusch et al., 1998), we
were surprised to identify a small but readily detectable popu-
lation of GFAP-expressing EGCs that were negative for this
transcription factor (Fig. 3c,d). This subset of EGCs could be
derived either from a previously uncharacterized Sox102 cell
lineage or from Sox101 precursors that down-regulate expres-
sion of Sox10 upon terminal differentiation. To distinguish
between these possibilities, we used Cre/LoxP technology to
fate map Sox10-expressing ENS progenitors in vivo. More
specifically, we combined the Sox10::Cre transgene, which
drives expression of Cre recombinase in all neural crest cell
lineages, with the Cre-dependent reporter Rosa26-ReYFP
(Laranjeira et al., 2011; Matsuoka et al., 2005). Expression of
Sox10 in these mice (called hereafter Sox10CrejYFP) would
be accompanied by induction of Cre and permanent activa-
tion of the Rosa26-ReYFP reporter irrespective of the contin-
ued activity of the Sox10 locus. By analyzing preparations of
the myenteric plexus from P90 Sox10CrejYFP mice, we
found that the majority (95.7%, 47 cells) of Sox102/GFAP1
cells expressed YFP, indicating that they are derived from
Sox101 progenitors (Fig. 5). These data confirm that all pop-
ulations of EGCs in the myenteric plexus are derived from
Sox10-expressing progenitors and suggest that the expression
of characteristic marker genes in EGC lineages can be highly
dynamic. The latter was confirmed when double immuno-
staining for GFAP, S100b, and Sox10 was performed on pri-
mary cultured EGCs derived from the myenteric plexus
(Supp. Info. Fig. 2). Although we found that the levels of
GFAP immunoreactivity did vary between individual cells in
culture, EGCs expressing only one of the markers were not
observed after 4 days in vitro. Thus, when EGCs are isolated
from their natural environment, and their spatial interactions
with other cell types in the gut wall are lost, they can no lon-
ger be distinguished based on their expression of GFAP,
S100b, or Sox10. Taken together, our experiments support
the phenotypic plasticity of EGC subtypes.
Dynamic Expression of GFAP in EGCs
Up-regulation of GFAP is one of the main features of reactive
astrogliosis, a hallmark of several central nervous system path-
ologies (Sofroniew, 2009). In the ENS, increased GFAP
expression has been demonstrated in inflammatory bowel dis-
ease patients, in mouse EGCs following ischemia and in
cytokine-treated cultures of rat EGCs (Cornet et al., 2001;
Thacker et al., 2011; von Boyen et al., 2004). Variation in
the levels of GFAP expression is also illustrated by the differ-
ent grades of GFAP immunoreactivity that we have observed
mostly in type-I EGCs (Fig. 3a,b). Although these studies
suggest a certain degree of plasticity in the molecular pheno-
type of EGCs, direct evidence for a temporal regulation of
glial-specific cell markers at the single-cell level in the ENS of
adult animals is currently not available. In addition, it
remains unclear whether the differential expression of GFAP
marks distinct sublineages of EGCs or represent mere fluctua-
tions in the levels of this protein in response to cell intrinsic
or environmental changes. To address these issues, we used
Cre/LoxP technology to follow over a period of several
FIGURE 5: Sox102 and Sox101 enteric glia are derived from a
common pool of Sox10 expressing progenitors. (a) Maximum
projection of a myenteric plexus preparation derived from a
Sox10CrejYFP mouse immunostained for YFP (green), Sox10
(red), and GFAP (gray), and counterstained with DAPI (blue).
Inset shows a Sox102/GFAP1 cell. (b–e) Break up of panels
showing the cell depicted in the inset in (a). Scale bars: 50 lm
(a), 20 lm (b–e). [Color figure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
Boesmans et al.: Enteric Glial Cell Heterogeneity
Month 2014 9
FIGURE 6: GFAP expression is highly dynamic in individual enteric glia. (a, b) Representative maximum projection of a myenteric plexus
preparation isolated from a GFAPCreERjYFP mouse in which 4-OHT was administered 2 (a) or 7 (b) days prior to tissue collection and
immunostaining for S100b (gray), YFP (green), and GFAP (red). Arrows points to YFP expressing cells that were not labeled by immuno-
staining for GFAP. (c) Quantification of single (YFP1) and double (GFAP1/YFP1) positive cells 2 or 7 days after 4-OHT administration
(***Fisher’s exact). A total of 164 (a) and 316 (b) cells were counted per experiment. Scale bars: 50 lm. [Color figure can be viewed in
the online issue, which is available at wileyonlinelibrary.com.]
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days the potential change in GFAP expression in a defined
population of GFAP1 EGCs. More specifically, mice hetero-
zygous for the hGFAP::CreERT2 transgene, which drives
expression of tamoxifen-inducible Cre recombinase under the
control of the human GFAP promoter (Ganat et al., 2006),
and the Cre-dependent Rosa26-ReYFP reporter (mice called
GFAPCreERjYFP), were administered 4-OHT and expression
of GFAP in YFP1 cells was analyzed in myenteric plexus
preparations 2 and 7 days later. As expected, 2 days after 4-
OHT administration, the vast majority of YFP1 EGCs (91%)
was also positive for GFAP (Fig. 6a). Interestingly, similar
analysis 7 days following 4-OHT injection showed that only
77% of YFP1 cells co-expressed GFAP (Fig. 6b). Since the
percentage of GFAP1 cells in the myenteric ganglia of adult
animals remains constant (Joseph et al., 2011; Stenkamp-
Strahm et al., 2013), these experiments suggest that under
physiological conditions expression of GFAP in individual
EGCs varies considerably over time.
Discussion
Traditionally, EGCs were thought to contribute primarily to
the structural integrity and nourishment of the ENS. However,
during the last decades several studies have confuted the con-
cept of a merely supportive function of EGCs and ascribed to
them a wide variety of roles that are essential for proper gastro-
intestinal function. Thus, in addition to being a scaffold for
neurons, EGCs function in mucosal integrity, neuroprotection,
adult neurogenesis, neuro-immune interactions, and synaptic
transmission (De Giorgio et al., 2012; Gulbransen and Shar-
key, 2012; Neunlist et al., 2013; Ruhl et al., 2004). Although
different morphological subtypes of EGCs have been described
previously (Hanani and Reichenbach, 1994), they are generally
thought to represent manifestations of a molecularly and physi-
ologically homogeneous multitasking cell population. Some
differences in the expression of receptors, channels, and
enzymes have been reported (Boesmans et al., 2013b, 2014;
Costagliola et al., 2009; Nasser et al., 2007, 2006b; Tjwa
et al., 2003), but so far no studies have addressed the intrinsic
heterogeneity of the recognized subtypes of EGCs. Recent in
vivo ablation models have advanced considerably our under-
standing of EGC function (Aube et al., 2006; Bush et al.,
1998; Cornet et al., 2001; Nasser et al., 2006a), but tissue dis-
ruption that encompasses relatively large cell populations is
likely to lead to general effects on gastrointestinal homeostasis
thus making it very difficult to pinpoint the relative contribu-
tion of EGC subtypes to the impaired epithelial barrier,
inflammation, and nerve defects that have been observed.
Here, we have employed a high resolution genetic mark-
ing technique which allowed us to label individual glial cells
of the gastrointestinal tract in situ and characterize their mor-
phological and physiological properties. Using this approach,
we have extended previous morphological studies and propose
that the complement of EGCs is subdivided into four sub-
types which correspond to unique locations within the plexus
and extraganglionic spaces. Although these subtypes share
many of the molecular markers that have been used to iden-
tify glial cells throughout the nervous system, they can be dis-
tinguished by the prevalence of marker expression across
different populations. In particular, GFAP, a marker used
widely for the identification of peripheral glial cells including
EGCs, is expressed primarily by type-I intraganglionic glial
cells but the majority of type-II and type-III EGCs are nega-
tive for this marker. Although GFAP has been implicated in
the morphological characteristics and adhesive properties of
astrocytoma cells (Sofroniew and Vinters, 2010), it is cur-
rently unclear whether the differential distribution of this
intermediate filament has a functional relevance or simply
reflects the sensitivity of type-I EGCs to GFAP-inducing sig-
nals. Irrespective of the physiological relevance of GFAP
expression, our data suggest that the morphologically distinct
subsets of EGCs express unique combinations of glial cell
markers in response to signals from their immediate microen-
vironment and/or as a result of functional specialization. Our
molecular studies so far have employed standard glial cell
markers that are widely expressed in other parts of the periph-
eral and central nervous system and which have been used
extensively in the ENS field. Systematic characterization of
the molecular profile of EGC subtypes is likely to uncover
unique combinations of additional molecules that can be
used for the further classification and study of EGCs. Combi-
natorial codes of marker molecules emerging from such stud-
ies will assist considerably further investigations on the roles
of EGCs in normal gut physiology and pathophysiology.
Heterogeneity among EGC subtypes could be develop-
mentally hard-wired by the differentiation of distinct glial cell
lineages emerging during embryogenesis. Alternatively, the
different subtypes of EGCs could originate from the same
glial cell precursors which, depending on their final destina-
tion, could give rise to morphologically and functionally dis-
tinct cell progeny. Developmental studies so far have failed to
identify distinct progenitors of EGCs and the markers used
so far are thought to label interchangeably a common progen-
itor (Heanue and Pachnis, 2007; Sasselli et al., 2012). More-
over, our lineage studies here argue for a considerable degree
of phenotypic plasticity among EGC subtypes in adult ani-
mals. Taken together, these findings support a model accord-
ing to which all subtypes of EGCs originate from a common
progenitor which, depending on its final location and physio-
logical context is capable of generating different glial sub-
types. Probably, the ability of glial cells to acquire different
properties is not restricted to embryonic or early postnatal
stages but is maintained throughout adult life pointing to a
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previously unrecognized degree of phenotypic plasticity of the
ENS. Given the high correlation between location of EGCs
within the plexus and phenotypic properties, it is currently
unclear whether the acquisition of new properties by glial
cells in adult animals is associated with cell translocation
between the different subdomains of the neuroglial networks
of the gut. Irrespective of the underlying cellular mechanisms,
our data indicate that EGCs are capable of adjusting their
phenotypic and molecular characteristics in response to con-
tinuous challenges associated with nutrition, microbiota,
mechanical factors, or disease.
Although the exact role of EGCs in the mechanisms
controlling the physiological output of the gut wall such as
peristalsis or secretion remains elusive (Broadhead et al.,
2012; MacEachern et al., 2011), previous studies have shown
that purines arising from both intrinsic enteric and sympa-
thetic neurons are the principal mediators of neuron-to-glia
communication in the ENS (Gomes et al., 2009; Gulbransen
and Sharkey, 2009; Gulbransen et al., 2010). Our experi-
ments provide further support to this model and highlight
the plausible role of type-I EGCs in integrating paracrine
neurogenic information and modulating neuronal activity
within the myenteric plexus (Boesmans et al., 2013b; Gul-
bransen and Sharkey, 2009). Although Ca21 imaging techni-
ques convincingly prove the activation of glial cells, the
functional consequences of intracellular Ca21 rises in EGCs
have yet to be established. Purinergic enteric neuron-to-glia
signaling is believed to be mediated via the purinergic recep-
tor subtype P2Y1 (Boesmans et al., 2013a; Gomes et al.,
2009; Gulbransen et al., 2012) but it is currently unclear
whether this receptor is not expressed by type-II and type-III
EGCs. Irrespective of the molecular mechanisms, the lack of
response to ATP by EGC subtypes II and III may reflect
developmental immaturity of the latter cell populations. This
idea is consistent with the reduced expression of GFAP in
these subpopulations, a marker thought to be expressed gen-
erally by mature EGCs (Jessen and Mirsky, 1980). Further
lineage tracing studies will be necessary to resolve these issues.
In conclusion, by combining genetic single-cell labeling,
in vivo fate mapping and live Ca21 imaging we provide evi-
dence that EGCs can not only be discriminated on the basis
of morphology and location but also display distinct molecu-
lar signatures and functional characteristics. Our studies set
the basis for further exploring the heterogeneity among
EGCs, which is a prerequisite to fully understand their role
in gastrointestinal function and disease.
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